Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer
Clinical trial NCT07161791 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07161791
- Sponsor
- Harbin Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-15
- Primary completion
- 2026-12-31
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.